Summit Therapeutics' stock tumbled after the FDA recommended a new trial for its lung-cancer drug following an extensive regulatory disclosure.
← Back to news feed
SMMT overview
SMMT
Summit Therapeutics Inc.
10.50
USD
-2.07
(-16.46%)since Nov 16, 2026
News about SMMT
5 stories shown
SMMTregulation
MarketWatch
Wall Street slid as software stocks experienced a heavy selloff ahead of Anthropic's expected IPO pricing and Nvidia's upcoming earnings report.
Benzinga
SMMTregulation
The FDA declined to approve Summit Therapeutics' lung-cancer drug because it needs to prove it can help people live longer.
MarketWatch
U.S. stock futures traded mixed on Monday while Treasury Secretary Scott Bessent pressed Nvidia over export compliance and several individual stocks made notable premarket moves.
Benzinga
SMMTregulation
The FDA declined approval for Summit Therapeutics' ivonescimab combined with chemotherapy as a treatment for advanced lung cancer due to insufficient evidence of longer survival.
Seeking Alpha